v3.26.3
Fair Value Measurements - Narrative (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Debt Instrument [Line Items]            
Asset impairment charges   $ 0   $ 0    
Contingent consideration obligations $ 121,500,000     121,500,000   $ 246,400,000
Contingent consideration obligations 152,400,000     152,400,000    
Contingent consideration related to the acquisition of Apellis 0   $ 0 4,100,000 $ 0  
Apellis Pharmaceuticals, Inc.            
Debt Instrument [Line Items]            
Contingent consideration related to the acquisition of Apellis $ 4,100,000     $ 4,100,000    
Minimum | Human Immunology Biosciences | Measurement Input, Probability Rate            
Debt Instrument [Line Items]            
Discount rate 0.750     0.750    
Maximum | Human Immunology Biosciences | Phase 3 Clinical Trial, Felzartamab AMR            
Debt Instrument [Line Items]            
Contingent consideration obligations     $ 150,000,000.0   $ 150,000,000.0  
Maximum | Human Immunology Biosciences | Measurement Input, Probability Rate            
Debt Instrument [Line Items]            
Discount rate 0.950     0.950